Germany's Protembis GmbH completes €30m Series B funding, co-led by VC investors, for its ProtEmbo® Cerebral Protection System clinical trial.

Germany's Protembis GmbH, a cardiovascular device firm, completed a €30 million Series B funding round, co-led by a European consortium of VC investors. The funds will support the enrollment of the PROTEMBO IDE Pivotal Trial for its ProtEmbo® Cerebral Protection System, protecting patients from brain injury in left-sided heart procedures. The company also added Dr. Keith D. Dawkins, an experienced cardiovascular specialist, to its Board of Directors.